Literature DB >> 27959768

PARP Inhibitors in Ovarian Cancer Treatment.

David R Spriggs1, Dan L Longo1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27959768     DOI： 10.1056/NEJMe1612843

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

1.  Journey's end: the quest for BRCA-like hereditary breast cancer genes is nearly over.

Authors:  W D Foulkes; P Polak
Journal:  Ann Oncol       Date:  2019-07-01       Impact factor: 32.976

2.  Comprehensive analysis of serum tumor markers and BRCA1/2 germline mutations in Chinese ovarian cancer patients.

Authors:  Hongyu Deng; Ming Chen; Xinwu Guo; Jianfu Heng; Xunxun Xu; Limin Peng; Hui Jiang; Guoli Li; Julia X Day; Jinliang Li; Dongyong Shan; Yinghua Li; Yanjie Zhou; Bin Liu; Lizhong Dai; Xiaochun Wang; Jun Wang
Journal:  Mol Genet Genomic Med       Date:  2019-04-10       Impact factor: 2.183

3.  A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers.

Authors:  Tingting Du; Zhihui Zhang; Jie Zhou; Li Sheng; Haiping Yao; Ming Ji; Bailing Xu; Xiaoguang Chen
Journal:  Front Pharmacol       Date:  2022-07-13       Impact factor: 5.988

4.  The Effect of CA125 Nadir Level on Survival of Advanced-Stage Epithelial Ovarian Carcinoma after Interval Debulking Surgery.

Authors:  Jing Zeng; Huizhen Huang; Ying Shan; Yan Li; Ying Jin; Lingya Pan
Journal:  J Cancer       Date:  2017-09-20       Impact factor: 4.207
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.